Leaderboards/autoimmune bullous skin diseases

autoimmune bullous skin diseases

Last updated June 11, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Carina Saggau
Christian-Albrechts-Universität zu Kiel
99
2
Alexander Scheffold
German Rheumatism Research Centre
90
3
Nina van Beek
University of Lübeck
70
4
Liang En Wee
National University of Singapore
60
5
Kelvin Bryan Tan
Ministry of Health
50
6
Yuqi Cheng
Anhui Medical University
40
7
Mikolaj Swiderski
University of Nottingham
20
8
Sonia Gran
University of Nottingham
10

Rising Stars Papers

1
Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases
Immunity|2024
62 cit.

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Dawoon Han
Yonsei University
99
2
Niccolò Capurro
University of Genoa
70
3
Zachary Hopkins
University of Utah
60
4
Zhi Hu
Central South University
50
5
Xiaolin Liu
Christian-Albrechts-Universität zu Kiel
40
6
Manuela Pigors
University of Lübeck
30
7
Chuqiao Xu
Shanghai Jiao Tong University
10

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Karin Jordan
University Hospital Heidelberg
99
2
Luis A. Díaz
Veterans Health Administration
90
3
F. Caux
Université Sorbonne Paris Nord
90
4
Dédée F. Murrell
St George Hospital
80
5
Enno Schmidt
University of Lübeck
80
6
Hiroshi Shimizu
Hokkaido University
70
7
Philippe Bernard
Université de Reims Champagne-Ardenne
60
8
Zhi Liu
University of North Carolina at Chapel Hill
50
9
Michael Hertl
RWTH Aachen University
40
10
Jinping Gao
Anhui Medical University
30

All-Time Leaders Papers

1
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
New England Journal of Medicine|2020
2.9k cit.
2
Immunotherapy in colorectal cancer: rationale, challenges and potential
Nature Reviews Gastroenterology & Hepatology|2019
2k cit.
3
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
The Lancet Oncology|2022
872 cit.
4
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
The Oncologist|2016
276 cit.
5
Type XVII collagen coordinates proliferation in the interfollicular epidermis
eLife|2017
141 cit.
6
Ultraviolet A-induced Production of Matrix Metalloproteinase-1 Is Mediated by Macrophage Migration Inhibitory Factor (MIF) in Human Dermal Fibroblasts
Journal of Biological Chemistry|2004
95 cit.
7
Tissue Regeneration Using Macrophage Migration Inhibitory Factor-Impregnated Gelatin Microbeads in Cutaneous Wounds
American Journal Of Pathology|2005
51 cit.
8
Blockade of Autoantibody-Initiated Tissue Damage by Using Recombinant Fab Antibody Fragments against Pathogenic Autoantigen
American Journal Of Pathology|2009
39 cit.
9
A life for autoimmune blistering diseases: in memoriam Detlef Zillikens
Frontiers in Immunology|2023
1 cit.
10
Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin
UNC Libraries|2020
0 cit.

Reagents for autoimmune bullous skin diseases

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

Acetyl-alpha-Tubulin (Lys40) (D20G3) Rabbit Monoclonal Antibody (SignalFlex™ mFluor™ UV375 Conjugate)

Cited in 5 papers
#19913$486
View Evidence →Agilent/Dako

IgG

#F0202
View Evidence →Agilent/Dako

IgG

#A0423
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Sin1 (D7G1A) Rabbit Monoclonal Antibody

Cited in 8 papers
#12860$161
View Evidence →Cell Signaling Technology

PTMScan® HS Asymmetric Di-Methyl Arginine Motif (adme-R) Kit

Cited in 7 papers
#18303$2,540
View Evidence →Agilent/Dako

C3c Complement

Cited in 6 papers
#F0201
View Evidence →